MHRA-100516-PIP01-22

Key Facts

PIPS Key Facts
Active Substance
Active Substance:
  • Toripalimab
Invented Name
  • Not available at present
  • TUOYI
PIP Number MHRA-100516-PIP01-22
Pharmaceutical form(s)
Pharmaceutical form(s):
  • Concentrate for solution for infusion
Therapeutic area
Therapeutic area:
  • Oncology
Conditions / Indications
Conditions / Indications:
  • Malignant neoplasms (except CNS, haematopoietic and lymphoid tissue and melanoma).
Route(s) of administration
Route(s) of administration:
  • Intravenous use
PIP applicant
Decision Type
Decision Type
W: decision granting a waiver in all age groups for the listed condition(s).
Compliance Check
Compliance Check
No
Compliance Check Decision Date
Compliance Check Procedure Number

Decision Document

PIPS Decision Documents
Decision Document Decision Document on a Paediatric Investigation Plan (PIP):Toripalimab.pdf
Published Date 03/11/2022